Last reviewed · How we verify
Arzerra
At a glance
| Generic name | Arzerra |
|---|---|
| Sponsor | GlaxoSmithKline |
| Target | B-lymphocyte antigen CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Chronic lymphoid leukemia, disease
- Relapsing multiple sclerosis
- Secondary progressive multiple sclerosis
Common side effects
Key clinical trials
- Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis (PHASE4)
- ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS (PHASE4)
- Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab (PHASE3)
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (PHASE2)
- Characterizing the Use of Ofatumumab in a Real World Setting
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (PHASE3)
- A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple Sclerosis
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |